Pari Ranganathan

ORCID: 0000-0002-0530-9045
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diet and metabolism studies
  • Gut microbiota and health
  • Clinical Nutrition and Gastroenterology
  • Dialysis and Renal Disease Management
  • Gastrointestinal motility and disorders
  • Diabetes Treatment and Management
  • Muscle metabolism and nutrition
  • Forest Management and Policy
  • Gout, Hyperuricemia, Uric Acid
  • Child Nutrition and Feeding Issues
  • Pharmacological Effects of Natural Compounds
  • Genetically Modified Organisms Research
  • Pharmaceutical studies and practices
  • Environmental Conservation and Management
  • Health Systems, Economic Evaluations, Quality of Life
  • Digestive system and related health
  • Liver Disease Diagnosis and Treatment

Kibow Biotech (United States)
2005-2021

National Institute of Diabetes and Digestive and Kidney Diseases
2006

Thomas Jefferson University
2006

Ghent University
2006

SUNY Downstate Health Sciences University
2006

State University of New York
2006

Primary goal of this randomized, double-blind, placebo-controlled crossover study Renadyl in end-stage renal disease patients was to assess the safety and efficacy measured through improvement quality life or reduction levels known uremic toxins. Secondary investigate effects on several biomarkers inflammation oxidative stress.Two 2-month treatment periods separated by washout crossover, with physical examinations, venous blood testing, questionnaires completed at each visit. Data were...

10.1155/2014/568571 article EN cc-by BioMed Research International 2014-01-01

Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular renal diseases. In chronic kidney disease, hyperuricemia extremely common, uric acid (UA) excretion relies on gut uricolysis by microbiota. Current therapy for lowering serum UA includes drugs that may produce undesired secondary effects. Therefore, this pilot study was designed to evaluate the potential of two probiotic supplements reduce systemic concentrations. Secondary objectives were...

10.1371/journal.pone.0202901 article EN cc-by PLoS ONE 2018-08-24

Chronic kidney disease may progress to end-stage renal disease, which requires dialysis or transplantation. No generally applicable therapies slow progression of are available. Bacteriotherapy affords a promising approach mitigate uremic intoxication by ingestion live microbes able catabolize solutes in the gut. The present study evaluates nonpathogenic soil-borne alkalophilic urease-positive bacterium Sporosarcina pasteurii (Sp) as potential urea-targeted component for such “enteric...

10.1097/01.mat.0000191345.45735.00 article EN ASAIO Journal 2006-01-01

The present study was to test the hypothesis that selected bacteria instilled into gastrointestinal tract could help in converting nitrogenous wastes accumulated due renal insufficiency nontoxic compounds; thereby, ameliorating biochemical imbalance. Herein we describe a prospective, blinded, placebo-controlled pilot study, using 5/6 th nephrectomized Sprague Dawley rat as chronic failure model. group consisted of 36 and 7 non-nephrectomized (control) rats. After two-week nephrectomy...

10.1100/tsw.2005.86 article EN cc-by The Scientific World JOURNAL 2005-01-01

Background: A synbiotic dietary supplement Renadyl™, which is being used by over 3000 CKD customers, was studied in a customer survey.The focus health status and Quality of Life (QoL).Methods: Survey questionnaires were sent to 951 current repeat customers Kibow Biotech Inc.Of those, 117 excluded due mailing errors other reasons.The final sample size 834.Results tabulated analysed using Statistical Analysis Software (SAS) V9.2 Microsoft MS Excel.Results: total 168 responses received (20%...

10.22259/ijrsmhs.0201004 article EN International Journal of Research Studies in Medical and Health Sciences 2017-01-01

Kibow Biotics®product is a mixture of three proprietary strains freeze-dried food grade bacteria, to ameliorate uremia. The product currently marketed in USA for chronic kidney diseased cats and Dogs. environmental variable associated with includes temperature extreme, humidity can have significant effect on viability product. purpose this study was evaluate the conditions, which Biotics®was subjected during international travel by measuring urea hydrolysis artificial intestinal fluid. Five...

10.1097/00002480-200603000-00310 article EN ASAIO Journal 2006-03-01

The aim of this study was to evaluate the viability as well urea catabolism commercial probiotics when exposed artificial gastro-intestinal (GI) conditions. increasing use improve general health and prevent incidence chronic diseases (eg., cardiovascular disease, diabetes, cancer) has become a major area interest within nutrition community. Trial twenty-five randomly chosen brands probiotic preparations were included in study. Products tested for microbiological content, hydrolysis GI...

10.1097/00002480-200503000-00234 article EN ASAIO Journal 2005-03-01
Coming Soon ...